drugset / Trial / NCT04805983
Evaluating the Safety, Tolerability, Pharmacokinetics and Receptor Occupancy of BMS-984923
Non-randomizedParallel-groupOpen-labelBasic science
Summary
This project seeks to develop a novel disease-modifying compound for Alzheimer's disease (AD).
Timeline
- Start
- 2021-03-25
- Primary completion
- 2022-04-24
- Completion
- 2022-04-24
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | BMS-984923 | Small molecule | 10 mg | — |
| Subject | BMS-984923 | Small molecule | 40 mg | — |
| Subject | BMS-984923 | Small molecule | 70 mg | — |
| Subject | BMS-984923 | Small molecule | 100 mg | — |
| Subject | BMS-984923 | Small molecule | 150 mg | — |
| Subject | BMS-984923 | Small molecule | 200 mg | — |